Efficacy of mycobacterium vaccae as an immunotherapeutic agent in the management of susceptible and multi-drug resistant pulmonary tuberculosis / Concepcion F. Ang [and five others]
Subject(s): Abstract: Patients who consulted at the TB Clinic of the Section of Infectious Diseases, Department of Medicine, UP-PGH and the Quezon Institute from January 1993 to June 1997 with microbiologically proven pulmonary tuberculosis based on a positive AFB smear and culture were included in the study. A total of 78 patients were classified as susceptible or uncomplicated TB while 65 patients were classified as multi-drug resistant TB or complicated TB. Both of the susceptible and multi-drug resistant tuberculosis were randomly assigned to either the immunotherapy (given an intradermal injection of Mycobacterium vaccae) or the non-immunotherapy group (without the intradermal injection of Mycobacterium vaccae). Using the time for sputum conversion to negativity in weeks as primary outcome, all of the patients were followed-up. Results show that for the susceptible or uncomplicated tuberculosis, there is an earlier conversion of sputum smear and culture to negativity in patients given the immunotherapy as compared to those who did not receive the immunotherapy (51.16 percent vs 40.00 percent at 2 weeks respectively). Conversion rates, however, became comparable by the 12th week of chemotherapy (90.70 percent vs 88.57 percent respectively). Secondary parameters of weight gain were likewise higher for the Immunotherapy Group as compared to the Non- Immunotherapy Group. For the multi-drug resistant or complicated cases, the mean time for sputum conversion was also compared between the immunotherapy and the non-immunotherapy group. Utilizing the Kruskal-Wallis one way analysis of variance , there was statistical significance. When we analyzed the effect of resistance to each drug on the time for sputum conversion to negativity utilizing the chi-square, only ethambutol and pyrazinamide were shown to have significance. This means that immunotherapy had a more beneficial effect on earlier sputum conversion when the resistance was to ethambutol or pyrazinamide.| Cover image | Item type | Current library | Home library | Collection | Shelving location | Call number | Materials specified | Vol info | URL | Copy number | Status | Notes | Date due | Barcode | Item holds | Item hold queue priority | Course reserves | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Journal Article
|
DOH Central Library Electronic Resource Section | J000029 (Browse shelf(Opens below)) | Available | D0001J000029 |
Patients who consulted at the TB Clinic of the Section of Infectious Diseases, Department of Medicine, UP-PGH and the Quezon Institute from January 1993 to June 1997 with microbiologically proven pulmonary tuberculosis based on a positive AFB smear and culture were included in the study. A total of 78 patients were classified as susceptible or uncomplicated TB while 65 patients were classified as multi-drug resistant TB or complicated TB. Both of the susceptible and multi-drug resistant tuberculosis were randomly assigned to either the immunotherapy (given an intradermal injection of Mycobacterium vaccae) or the non-immunotherapy group (without the intradermal injection of Mycobacterium vaccae).
Using the time for sputum conversion to negativity in weeks as primary outcome, all of the patients were followed-up. Results show that for the susceptible or uncomplicated tuberculosis, there is an earlier conversion of sputum smear and culture to negativity in patients given the immunotherapy as compared to those who did not receive the immunotherapy (51.16 percent vs 40.00 percent at 2 weeks respectively). Conversion rates, however, became comparable by the 12th week of chemotherapy (90.70 percent vs 88.57 percent respectively).
Secondary parameters of weight gain were likewise higher for the Immunotherapy Group as compared to the Non- Immunotherapy Group. For the multi-drug resistant or complicated cases, the mean time for sputum conversion was also compared between the immunotherapy and the non-immunotherapy group. Utilizing the Kruskal-Wallis one way analysis of variance , there was statistical significance. When we analyzed the effect of resistance to each drug on the time for sputum conversion to negativity utilizing the chi-square, only ethambutol and pyrazinamide were shown to have significance. This means that immunotherapy had a more beneficial effect on earlier sputum conversion when the resistance was to ethambutol or pyrazinamide.
In: Acta Medica Philippina, 2006 vol. 40 (2) pages: 20-27
There are no comments on this title.